Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas

AIM: To assess the patient-reported outcomes (PROs) of pancreatic neuroendocrine tumor (PNET) patients. METHODS: Fifty-one consecutive patients (21 male,30 female, 61.0 ± 10.3 years) with proven PNETs were studied. An SF-12 questionnaire capable of exploring the physical (PCS) and mental (MCS) aspects of daily life was used. Four questionnaires were also used [12 items General Health Questionnaire (GHQ-12) for nonpsychotic psychiatric disorders, State Trait Anxiety Inventory (STAI) Y-1 and Y-2 for anxiety and BDI-Ⅱ for depressive symptoms] to explore the psychological aspects of the disease. Forty-four sex- and age-matched Italian normative subjects were included and evaluated using the SF-12, STAI Y-1 and Y-2 questionnaires.RESULTS: Seven patients refused to participate to the study; they were clinically similar to the 44 participants who agreed to complete the questionnaires. PNET patients had a PCS score (44.7 ± 11.0) were not significantly different from the norms (46.1 ± 9.9, P = 0.610), whereas the MCS score was significantly lower in patients (42.4 ± 13.0) as compared to the norms (48.2 ± 9.8, P = 0.036). GHQ-12 identified 11 patients (25.0%) as having non-psychotic psychiatric disorders. The STAI scores were similar in the patients and in the normative population. Finally, BDI-Ⅱ identified eight patients (18.2%) with moderate depression and 9 (20.5%) with mild depression whereas 27 patients (61.4%) had no depression. CONCLUSION: The PNET patients had a good physical but an impaired mental component of their quality of life; in addition, mild or moderate depressive symptoms are present in about 40% of PNET patients.     

升降汤对小鼠胃肠蠕动及胃肠激素的影响

目的 :探讨中药升降汤对胃肠蠕动的作用及对胃肠激素的影响。方法 :①观察小鼠用升降汤高、中、低剂量灌胃后碳素墨水在小肠的移动长度 ,并与蒸馏水灌胃对照组进行对比观察 ;②用放射免疫分析法同步测定升降汤灌胃 1 0d后 ,小鼠小肠组织胃动素和生长抑素水平。结果 :升降汤高、中、低剂量组碳素墨水在小鼠小肠的推进率分别为 ( 96 .1 6± 3.2 7) % ,( 94 .0 2± 3.4 5 ) % ,( 81 .4 2±5 .1 8) % ,对照组为 ( 5 9.2 6± 5 .2 4 ) % ;升降汤组与对照组比较 ,有显著性差异 (P <0 .0 5或P <0 .0 1 )。升降汤高剂量组小肠湿组织胃动素为 ( 8.71± 1 .0 7)ng/g ,生长抑素为 ( 2 4 .0 7±2 .91 )ng/g;对照组分别为 ( 7.5 9± 0 .85 )ng/g ,( 30 .83± 3.6 9)ng/g,两组均有显著性差异 (P<0 .0 5或P <0 .0 1 )。结论 :升降汤可促进小鼠的胃肠蠕动 ,提高小鼠小肠组织的胃动素及降低生长抑素水平     

胃炎康胶囊对慢性胃病患者胃窦D细胞的影响

目的：观察胃炎康胶囊对慢性胃病患生长抑素内分泌细胞(胃窦D细胞)的影响。方法：用免疫组化酶链亲合素过氧化酶复合技术(SABC)对患治疗前后胃黏膜组织的D细胞染色,观察治疗前后D细胞的形态和数量变化。结果：经胃炎康胶囊治疗后,患胃窦黏膜D细胞阳性数及强阳性率均明显下降,差异有显性。结论：胃炎康胶囊对慢性胃病患生长抑素D细胞有调整作用。     

原发性肝癌患者肿瘤组织生长抑素受体表达与血AFP水平的相关性

背景与目的:生长抑素类似物(somatostatin analogue,SSTA)对部分原发性肝癌(hepatocellular carcinoma,HCC)患者具有一定疗效,但HCC患者肿瘤组织中生长抑素受体(somatostatin receptor,SSTR)表达状况不详,其与血甲胎蛋白(alphafetoprotein,AFP)的相关性也未见探讨.本研究拟了解肝癌组织中SSTR1、SSTR2、SSTR3、SSTR4及SSTR5亚型的表达状况及其与血AFP的相关性.方法:逆转录-聚合酶链反应及免疫组织化学法分别检测人肝癌及肝硬化组织(各40例)SSTR1、SSTR2、SSTR3、SSTR4及SSTR5亚型的mRNA及蛋白表达:酶联免疫吸附试验检测HCC患者肿瘤组织及外周血AFP水平.结果:肝癌组织中SSTR1、SSTR2、SSTR3、SSTR4及SSTR5蛋白阳性率(分别为47.5%、70.0%、50.0%、65.0%及67.5%)显著高于肝硬化组织(分别为55.0%、67.5%、52.5%、60.0%及47.5%).肝癌组织中SSTR1、SSTR2、SSTR3、SSTR4及SSTR5表达与患者血AFP水平呈二次曲线正相关(r依次为0.882、0.901、0.877、0.854、0.903,P＜0.05).血AFP水平在200～800 μg/L范围时,伴有肝癌组织SSTRs的高表达,过低或过高的血AFP水平伴有SSTR低表达.结论:约60%HCC患者的肿瘤组织表达了SSTRs,其表达量明显高于肝硬化组织;15 AFP水平在200-800μg/L的HCC患者伴有肝癌组织SSTRs的高表达,提示为SSTA治疗的适宜候选者.     

胰岛素泵治疗2型糖尿病中联用生长抑素的研究

2型糖尿病(T2DM)发病的两个主要环节是胰岛素抵抗和β细胞功能衰竭。目前研究的是针对糖尿病胰腺β细胞如何更好保护其功能,甚至恢复其功能、延缓其衰竭,以达到更好的临床治疗效果。本研究前瞻性观察胰岛素泵联用生长抑素治疗新诊断T2DM患者C肽恢复情况。现报告如下。1研究对象     

内镜下套扎术联用生长抑素不同时程治疗食管静脉曲张破裂出血的效果分析

目的探讨内镜下套扎术联用生长抑素不同时程治疗食管静脉曲张破裂出血的效果。方法选择我院2008年1月～2018年5月收治的180例食管静脉曲张破裂出血患者,经内镜下套扎术后根据生长抑素使用天数分成三组:生长抑素3 d组、生长抑素5 d组和生长抑素7 d组;分析7 d内、7～14 d和7～42 d内再出血率、总止血率、成本、成本-效果比、并发症和副反应发生率。结果生长抑素3 d组、生长抑素5 d组和生长抑素7 d组的7 d内再出血率、7～14 d内再出血率和7～42 d内再出血率比较,差异均无统计学意义(P0.05);三组总止血率比较,差异无统计学意义(P0.05);三组的成本及成本-效果比比较,生长抑素3 d组的成本及成本-效果比均为最低;三组的并发症及副反应发生率比较,差异均无统计学意义(P0.05)。结论内镜下套扎术联用生长抑素3 d能达到有效时程,其效果与5 d时程及7 d时程效果相同,不必延长使用时间。     

Somatostatin analogues and the risk of post-operative pancreatic fistulas after pancreatic resection - A systematic review & meta-analysis

BackgroundPost-operative pancreatic fistula (POPF) is a common complication of pancreatic resection. Somatostatin analogues (SA) have been used as prophylaxis to reduce its incidence. The aim of this study is to appraise the current literature on the effects of SA prophylaxis on the prevention of POPF following pancreatic resection.MethodsThe review of the literature was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data from studies that reported the effects of SA prophylaxis on POPF following pancreatic resection were extracted, to determine the effect of SA on POPF morbidity and mortality.ResultsA total of 15 studies, involving 2221 patients, were included. Meta-analysis revealed significant reductions in overall POPF (Odds ratio: 0.65 (95% CI 0.53–0.81, p < 0.01)), clinically significant POPF (Odds ratio: 0.53 (95% CI 0.34–0.83, p < 0.01)) and overall morbidity (OR: 0.69 (95% CI: 0.50–0.95, p = 0.02)) following SA prophylaxis. There is no evidence that SA prophylaxis reduces mortality (OR: 1.10 (95%CI: 0.68–1.79, p = 0.68)).ConclusionSA prophylaxis following pancreatic resection reduces the incidence of POPF. However, mortality is unaffected.     

The monoclonal antibody Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal human hypothalamus and adjoining areas

The monoclonal antibody Alz-50 is directed against Alzheimer's disease-related modified tau proteins and reveals cytoskeletal changes, i.e. neurofibrillary tangles and dystrophic neurites. The present study shows that, in the hypothalamus of non-demented control subjects, this same antibody gives a distinctive staining pattern of a subpopulation of somatostatin neurons and beaded fibers. Furthermore, Alz-50 occasionally recognizes somatostatin-containing cell bodies and dystrophic neurite-like fibers in the (neuritic) senile plaques of AD patients. These observations have direct consequences for the interpretation of Alz-50 staining in diagnostic usage and for the assessment of Alzheimer's disease-like changes induced by β-amyloid in experimental animal brains. On dot spotting, Alz-50 was found to bind to a number of fragments from the somatostatin precursor, of which somatostatin_15–28 stained best. Preadsorption of Alz-50 by somatostatin_15–28, as well as other specificity tests, failed, however, to provide any clue to the nature of the unknown compound(s) stained in the control hypothalamus.